Alto Neuroscience (NYSE:ANRO) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Alto Neuroscience (NYSE:ANRO) announced its quarterly earnings data on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Stock Up 6.0 %

Shares of NYSE ANRO traded up $0.27 during trading hours on Wednesday, hitting $4.77. The stock had a trading volume of 303,888 shares, compared to its average volume of 373,232. The firm’s 50-day moving average price is $10.20 and its two-hundred day moving average price is $11.50. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04. Alto Neuroscience has a 52 week low of $3.61 and a 52 week high of $24.00.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ANRO shares. Rodman & Renshaw cut Alto Neuroscience from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus decreased their target price on Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday. William Blair restated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. RODMAN&RENSHAW lowered Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Wedbush lowered Alto Neuroscience from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $29.00 to $4.00 in a research report on Wednesday, October 23rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Alto Neuroscience presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.